E2F1 and lung cancer: Furthermore, overexpression of E2F1 significantly shortened overall survival (OS) in lung cancer patients observed over 200 months, while this trend was also noted in hepatocellular carcinoma (HCC) patients (Gao et al., 2016; Liu Y. et al., 2022).